Explore more publications!
Tech Times Kuwait
Got News to Share?

Tech Times Kuwait: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Times Kuwait.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 10, 2025

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
December 10, 2025

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Indeterminate GlobeNewswire
Clearmind Medicine Announces 1-for-40 Reverse Share Split
December 10, 2025

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Indeterminate GlobeNewswire
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
December 10, 2025

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Indeterminate GlobeNewswire
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
December 10, 2025

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Indeterminate GlobeNewswire
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
December 10, 2025

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Indeterminate GlobeNewswire
Observe.AI named a Leader in the IDC MarketScape: AI-Enabled Contact Center Workforce Engagement Management 2025-2026 Vendor Assessment
December 10, 2025

Observe.AI named a Leader in the IDC MarketScape: AI-Enabled Contact Center Workforce Engagement Management 2025-2026 Vendor Assessment

Indeterminate GlobeNewswire
Four Points Technology Awarded a 2025 AWS Partner Award
December 10, 2025

Four Points Technology Awarded a 2025 AWS Partner Award

Indeterminate GlobeNewswire
Photonic Sets New Standard with Distributed Quantum Resource Estimation
December 10, 2025

Photonic Sets New Standard with Distributed Quantum Resource Estimation

Indeterminate GlobeNewswire
Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
December 10, 2025

Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer

Indeterminate GlobeNewswire
TP in Indonesia Launches TP.ai FAB, Driving the Future of Intelligent, Human-Centered Operations
December 10, 2025

TP in Indonesia Launches TP.ai FAB, Driving the Future of Intelligent, Human-Centered Operations

Indeterminate GlobeNewswire
Persephone Biosciences Announces Publication in Cell Host & Microbe Highlighting the Critical Need to Restore Bifidobacterium in the Infant Gut Microbiome
December 10, 2025

Persephone Biosciences Announces Publication in Cell Host & Microbe Highlighting the Critical Need to Restore Bifidobacterium in the Infant Gut Microbiome

Indeterminate GlobeNewswire
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique
December 10, 2025

GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique

Indeterminate GlobeNewswire
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy  
December 10, 2025

GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy  

Indeterminate GlobeNewswire
Striim Releases Validata to Ensure Data Accuracy and Deliver Trusted AI
December 10, 2025

Striim Releases Validata to Ensure Data Accuracy and Deliver Trusted AI

Indeterminate GlobeNewswire
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
December 10, 2025

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

Indeterminate GlobeNewswire
Valneva annonce des résultats finaux de Phase 2 positifs sur la persistance des anticorps et l’innocuité de son vaccin contre le chikungunya IXCHIQ® chez les enfants
December 10, 2025

Valneva annonce des résultats finaux de Phase 2 positifs sur la persistance des anticorps et l’innocuité de son vaccin contre le chikungunya IXCHIQ® chez les enfants

Indeterminate GlobeNewswire
WeVisu Announces National Expansion as Platform Adoption Surges 300 Percent Year Over Year Across the U.S. Remodeling Industry
December 10, 2025

WeVisu Announces National Expansion as Platform Adoption Surges 300 Percent Year Over Year Across the U.S. Remodeling Industry

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions